Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles, route de Lennik 808, 1070 Brussels, Belgium.
Crit Care. 2010;14(1):R15. doi: 10.1186/cc8872. Epub 2010 Feb 9.
Biomarkers can be useful for identifying or ruling out sepsis, identifying patients who may benefit from specific therapies or assessing the response to therapy.
We used an electronic search of the PubMed database using the key words "sepsis" and "biomarker" to identify clinical and experimental studies which evaluated a biomarker in sepsis.
The search retrieved 3370 references covering 178 different biomarkers.
Many biomarkers have been evaluated for use in sepsis. Most of the biomarkers had been tested clinically, primarily as prognostic markers in sepsis; relatively few have been used for diagnosis. None has sufficient specificity or sensitivity to be routinely employed in clinical practice. PCT and CRP have been most widely used, but even these have limited ability to distinguish sepsis from other inflammatory conditions or to predict outcome.
生物标志物可用于识别或排除败血症，确定可能受益于特定治疗的患者，或评估治疗反应。
我们使用 PubMed 数据库的电子搜索，使用关键词“败血症”和“生物标志物”来识别评估败血症中生物标志物的临床和实验研究。
搜索共检索到 3370 篇参考文献，涵盖了 178 种不同的生物标志物。
已经评估了许多生物标志物在败血症中的应用。大多数生物标志物已经在临床上进行了测试，主要作为败血症的预后标志物；用于诊断的相对较少。没有一种标志物具有足够的特异性或灵敏度，可以在临床实践中常规使用。降钙素原和 C 反应蛋白应用最广泛，但即使是这些标志物，也很难区分败血症与其他炎症性疾病，或预测结局。
